European Notebook: U.S. Investors Tap Into Europe; New U.K. Pricing Scheme; Pfizer Dismayed By German Payers
Executive Summary
Europe's IPO window remains closed but the region still attracts U.S. investors; drug spending set to decline in Greece and Spain in 2014; Pfizer takes Bosulif off the German market because agreement on price unlikely with health insurers; no room for value-based pricing in the U.K.; European Parliament clears €80 billion in research funding under Horizon 2020.